Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16844582 | 0.84 | MAPT (0.49) | ABCB1HTR1AMAOBTDP1 | |
| SCHEMBL266254 | 0.77 | KDM4E (0.56) | PTK2ABCB1 | |
| SCHEMBL6816442 | 0.77 | MAOB (0.46) | ABCB1HTR1AMAOB | |
| SCHEMBL2046418 | 0.77 | ABCB1 (0.49) | PTK2ABCB1 | |
| SCHEMBL7280823 | 0.76 | MAOA (0.53) | MAOBTDP1 | |
| SCHEMBL6849962 | 0.75 | ABCB1 (0.41) | PTK2ABCB1 | |
| SCHEMBL4812829 | 0.75 | MAOA (0.47) | MAOB | |
| SCHEMBL16018989 | 0.74 | ABCB1 (0.68) | NPC1RAB9AABCB1HTR1AADRA1D | |
| SCHEMBL12634878 | 0.74 | ABCB1 (0.49) | PTK2ABCB1HTR1AHTR2AHTR2B | |
| SCHEMBL12634774 | 0.73 | ABCB1 (0.44) | ABCB1MAOBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105540-A1 | 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105540-A1 | 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105540-A1 | 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| WO-2011053507-A1 | 2-AMINO-9-[4-(4-METHOXY-PHENOXY) - PIPERID IN -1-YL] -4-PHENYL-INDENO [1,2-D] PYRIMIDIN -5 -ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053511-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053510-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPY-RIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105540-A1 | 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST | ADORA2A, ADORA1, ADORA3 | PTK2 2537/4885NPC1 2187/4885RAB9A 878/4885 |
| US-20110105494-A1 | HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | PTK2 3322/4885NPC1 3695/4885RAB9A 1941/4885 |
| US-20110105493-A1 | HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | PTK2 3342/4885NPC1 4145/4885RAB9A 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.